A 18F-labeled adnectin targeting human PD-L1 (BMS-986192), has recently been tested in non-small lung cancer patients in a first-in-human clinical trial, confirming a correlation between tumor uptake of the tracer and both PD-L1 expression using IHC and clinical response to Nivolumab, a PD-1 blockade therapy (Figure 4D) 120. This evidence concerns the gene PDCD1 and neoplasm.